Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to observe patients with Type 2 Diabetes on basal insulin alone or basal insulin with oral agents can be efficiently and safely started with meal time insulin using U100 rapid acting insulin analog and V-Go® Disposable Insulin Delivery Device (V-Go) using one of two dose titration algorithms to achieve improved A1C at 4 months.


Clinical Trial Description

This study addresses the informational needs of Primary Care Physicians with regard to providing insulin dosing and titration information utilizing a V-Go disposable insulin delivery device. We look to compare two treatment arms of insulin dosing and titration in patients with Type 2 insulin-dependent diabetes - a fixed dose titration arm, and an arm where 50% of the insulin dose is given at the largest meal of the day. This study will provide practical information on glycemic control, dose requirements and safety in patients with Type 2 diabetes on basal insulin with or without oral anti-diabetic agents who are being primarily managed in the primary care office. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02361489
Study type Interventional
Source Valeritas, Inc.
Contact Karrie A Hilsinger, BA
Phone 908-927-9920
Email khilsinger@valeritas.com
Status Recruiting
Phase Phase 4
Start date February 2015
Completion date April 2016

See also
  Status Clinical Trial Phase
Completed NCT01713764 - A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics Phase 2
Completed NCT01121315 - A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care N/A
Completed NCT02773095 - Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative N/A
Completed NCT02184455 - Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment Phase 1
Completed NCT02326129 - Novel Biomarker for Development of T2D
Not yet recruiting NCT02074540 - The Influence of Health Beliefs and Uncertainty on Diabetes Type II Patient Compliance N/A